Psychedelics Optimi Health launches ibogaine initiative in response to Trump’s executive order Psychedelic stocks surged after the president gave his signature Rowan DunneApril 21, 2026
Medical and Pharmaceutical Amgen and BeOne Medicines get Chinese approval for small cell lung cancer drug The authorization could help facilitate significant revenue growth Rowan DunneApril 12, 2026
Medical and Pharmaceutical bioAffinity Technologies soars Monday as non-invasive lung cancer tech gains traction Shares rose by 73% during the session with no immediate catalyst Rowan DunneMarch 23, 2026
Medical and Pharmaceutical Immutep completely tanks after discontinuing lung cancer drug trial Shares dropped by 88% on Friday the 13th, leaving investors shook Rowan DunneMarch 16, 2026
Medical and Pharmaceutical Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics Shares surged by 16% after the deal was announced Rowan DunneMarch 2, 2026
Medical and Pharmaceutical Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test The ctDNA blood draw is known for its ultrasensitive detection capabilities Rowan DunneFebruary 10, 2026
Cannabis Pakistani cabinet approves national framework for medical cannabis regulation The move builds on Pakistan's decision to legalize industrial hemp and medical cannabis in 2020 Rowan DunneJanuary 26, 2026
Psychedelics Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules Lead drug candidate EB-301 is structurally similar to DMT Rowan DunneDecember 11, 2025
AI and Autonomy Eli Lilly launches AI-powered drug development platform for biotech operators 'TuneLab' allows biotech companies to securely use Eli Lilly's AI models to gain insights about their IP Rowan DunneSeptember 10, 2025
Psychedelics Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic One of the biggest deals of all time in the industry Rowan DunneAugust 27, 2025